Header

Why Glyxambi®?

img

Powerful Efficacy.
Ensured Safety.
Convenient Dosing.

CV safety

Glyxambi® is not indicated for treatment of HF or CKD.

FDC: Fixed-dose combination. CV: Cardiovascular. CKD: Chronic kidney disease. HF: Heart failure.

References:

  1. Zinman B, et al. N Engl J Med. 2015;373(22):2117-2128.

  2. Rosenstock J, et al. JAMA. 2019;321(1):69-79.

  3. Rosenstock J, et al. JAMA. 2019;322(12):1155-1166.

Cardiovascular safety

CV death reduction in T2DM patients with CVD1

CV safety 2

Glyxambi® is not indicated for treatment of HF or CKD. * Nominal p-value. † The 38% RRR in CV death was achieved in the overall EMPA-REG OUTCOME® population for the duration of the trial.
‡ Pooled data from 10 mg and 25 mg doses of Jardiance®; both doses showed a comparable reduction in the risk of CV death. # Prespecified microvascular endpoint in CARMELINA® trial.

FDC: Fixed -dose combination. CV: Cardiovascular. CVD: Cardiovascular disease. EMPA: Empagliflozin. 3P-MACE: 3-point major adverse cardiovascular events. LINA: Linagliptin. HR: Hazard ratio. RRR: Relative risk reduction. hHF: Hospitalisation due to heart failure. Cl: Confidence interval. T2DM: Type 2 diabetes mellitus. CKD: Chronic kidney disease. HF: Heart failure.

References:

  1. Zinman B, et al. N Engl J Med. 2015;373(22):2117-2128.

  2. Rosenstock J, et al. JAMA. 2019;321(1):69-79.

  3. Rosenstock J, et al. JAMA. 2019;322(12):1155-1166.

Reduction of all-cause death in T2DM patients with CVD¹

cv safety

Glyxambi® is not indicated for treatment of HF or CKD. * Nominal p-value. † The 38% RRR in CV death was achieved in the overall EMPA-REG OUTCOME® population for the duration of the trial. 
‡ Pooled data from 10 mg and 25 mg doses of Jardiance®; both doses showed a comparable reduction in the risk of CV death. # Prespecified microvascular endpoint in CARMELINA® trial.

FDC: Fixed -dose combination. CV: Cardiovascular. CVD: Cardiovascular disease. EMPA: Empagliflozin. 3P-MACE: 3-point major adverse cardiovascular events. LINA: Linagliptin. HR: Hazard ratio. RRR: Relative risk reduction. hHF: Hospitalisation due to heart failure. Cl: Confidence interval. T2DM: Type 2 diabetes mellitus. CKD: Chronic kidney disease. HF: Heart failure.

References:

  1. Zinman B, et al. N Engl J Med. 2015;373(22):2117-2128.

  2. Rosenstock J, et al. JAMA. 2019;321(1):69-79.

  3. Rosenstock J, et al. JAMA. 2019;322(12):1155-1166.

Long-term CV & renal safety with potential albuminuria benefits1,2

cv safety

Glyxambi® is not indicated for treatment of HF or CKD. * Nominal p-value. † The 38% RRR in CV death was achieved in the overall EMPA-REG OUTCOME® population for the duration of the trial.
‡ Pooled data from 10 mg and 25 mg doses of Jardiance®; both doses showed a comparable reduction in the risk of CV death. # Prespecified microvascular endpoint in CARMELINA® trial.

FDC: Fixed -dose combination. CV: Cardiovascular. CVD: Cardiovascular disease. EMPA: Empagliflozin. 3P-MACE: 3-point major adverse cardiovascular events. LINA: Linagliptin. HR: Hazard ratio. RRR: Relative risk reduction. hHF: Hospitalisation due to heart failure. Cl: Confidence interval. T2DM: Type 2 diabetes mellitus. CKD: Chronic kidney disease. HF: Heart failure.

References:

  1. Zinman B, et al. N Engl J Med. 2015;373(22):2117-2128.

  2. Rosenstock J, et al. JAMA. 2019;321(1):69-79.

  3. Rosenstock J, et al. JAMA. 2019;322(12):1155-1166.